Log in
Enquire now
‌

US Patent 11001588 Activating pyruvate kinase R and mutants thereof

Patent 11001588 was granted and assigned to FORMA Therapeutics on May, 2021 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors
Is a
Patent
Patent
0
Current Assignee
FORMA Therapeutics
FORMA Therapeutics
0
Date Filed
September 19, 2019
0
Date of Patent
May 11, 2021
0
Patent Applicant
FORMA Therapeutics
FORMA Therapeutics
0
Patent Application Number
16575456
0
Patent Citations
‌
US Patent 10100043 Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
‌
US Patent 10208052 Compositions for activating pyruvate kinase
‌
US Patent 10266551 Compounds and uses thereof for the modulation of hemoglobin
‌
US Patent 10315991 Compounds and uses thereof for the modulation of hemoglobin
‌
US Patent 10377741 Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
‌
US Patent 10435393 Compounds and uses thereof for the modulation of hemoglobin
‌
US Patent 10450269 Compounds and uses thereof for the modulation of hemoglobin
‌
US Patent 10472371 Compositions for activating pyruvate kinase
‌
US Patent 10493035 Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
‌
US Patent 10577345 Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
•••
Patent Inventor Names
Neal Green
0
David Richard
0
Gary Gustafson
0
Lorna Mitchell
0
Anna Ericsson
0
David R. Lancia, Jr.
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
11001588
0
Patent Primary Examiner
‌
Charanjit Aulakh
0

Find more entities like US Patent 11001588 Activating pyruvate kinase R and mutants thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.